Chief Minister A. Revanth Reddy is set to inaugurate BioAsia 2026, the next edition of Asia’s leading life sciences and health-tech forum, in Hyderabad on February 17.
The 23rd in the annual series, the edition with “TechBio Unleashed: AI, Automation and the Biology Revolution” as the theme, will bring together policy-makers, global biotech and pharma leaders, including from Amgen, Sanofi and Eli Lilly, and regulators.
Union Ministers Piyush Goyal and Ashwini Vaishnaw, and Telangana IT and Industries Minister D. Sridhar Babu will be participating along with some of the most influential voices across biotechnology, pharmaceuticals, healthcare, medtech, AI, and advanced manufacturing at the two-day event, the organisers said on Thursday.
Bruce L. Levine, Professor of Cancer Gene Therapy, University of Pennsylvania; Howard Y. Chang, Chief Scientific Officer and SVP Global Research of Amgen, Stefan Miltenyi, founder and president of Miltenyi Biotec & Madeliene Roach, EVP – Global Business Services of Sanofi will deliver keynote addresses. Ajay Kumar Sood, Principal Scientific Adviser to the government of India and Rajeev Singh Raghuvanshi, Drug Controller General of India are also scheduled to address the gathering.
Google DeepMind V-P of Science Pushmeet Kohli will bring perspectives from the frontier of AI —highlighting how foundational models, protein science breakthroughs, and advanced reinforcement learning are accelerating discovery across biology and medicine.
Members of the leadership team of Dr.Reddy’s Laboratories, Zydus, Biocon and Cipla will take part in a CEO Conclave on ‘Future of Pharma and Biotech.
Senior leaders from Novartis, Roche, Novo Nordisk, Medtronic, Merck, BMS, Takeda, Lonza, Charles River Laboratories, Ginkgo Bioworks and AstraZeneca will cover various topics, including GCCs as innovation engines and next-generation biologics, cell and gene therapies, mRNA and radiopharmaceuticals at the panel discussions.
BioAsia will examine how Artificial Intelligence (AI), advanced biology and intelligent manufacturing are converging to fundamentally transform how therapies are discovered, developed, and delivered worldwide. As biology becomes increasingly programmable and AI rapidly compresses research and development and manufacturing timelines, the TechBio paradigm is moving from experimentation to execution. BioAsia 2026 will serve as a platform convening leaders who are actively shaping AI-driven discovery platforms, next-generation biologics and digitally integrated operating models across global healthcare.
A dedicated session on Telangana Rising Vision 2047 will outline the State’s roadmap for innovation-led growth across advanced modalities, AI-enabled R&D and next-generation biomanufacturing, the organisers said.
Published – February 05, 2026 08:35 pm IST
